Thus, high-dose testosterone therapy may enhance sensitivity to YM155 in castrate prostate cancer patients with low tumoral SLC35F2 expression by inducing SLC35F2, while high SLC35F2 expression at baseline serving as biomarker to select patients who may be immediate candidates for YM155 treatment. The gene discussed is SLC35F2; the disease is prostate carcinoma.